Cargando…

Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL

Detalles Bibliográficos
Autores principales:	Artykov, Artem A., Yagolovich, Anne V., Dolgikh, Dmitry A., Kirpichnikov, Mikhail P., Trushina, Daria B., Gasparian, Marine E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883345/ https://www.ncbi.nlm.nih.gov/pubmed/35237612 http://dx.doi.org/10.3389/fcell.2021.820069

Ejemplares similares

Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL
por: Artykov, Artem A., et al.
Publicado: (2021)

Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH–DR5-B with Dual VEGFR2 and DR5 Receptor Specificity
por: Yagolovich, Anne V., et al.
Publicado: (2022)

Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B More Efficiently Than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors
por: Artykov, Artem A., et al.
Publicado: (2020)

Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile
por: Yagolovich, Anne V., et al.
Publicado: (2020)

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells
por: Yagolovich, Anne, et al.
Publicado: (2021)

Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4
por: Bychkov, Maxim L., et al.
Publicado: (2014)

DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma
por: Yagolovich, Anne V., et al.
Publicado: (2022)

Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant for Targeted Drug Delivery to Tumor Cells
por: Gileva, Anastasia, et al.
Publicado: (2023)

Recent Advances in the Development of Nanodelivery Systems Targeting the TRAIL Death Receptor Pathway
por: Yagolovich, Anne V., et al.
Publicado: (2023)

ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL
por: Mishukov, Artem, et al.
Publicado: (2022)

Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
por: van Geelen, Caroline MM, et al.
Publicado: (2011)

Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2
por: Jeong, Dongjin, et al.
Publicado: (2021)

Endocytosis and the recycling of plasma membrane
Publicado: (1983)

Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation
por: Qiao, Chunxia, et al.
Publicado: (2012)

Targeting AML through DR4 with a novel variant of rhTRAIL
por: Szegezdi, Eva, et al.
Publicado: (2011)

Activation of TRAIL‐DR5 pathway promotes sensorineural degeneration in the inner ear
por: Kao, Shyan‐Yuan, et al.
Publicado: (2016)

Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer
por: Kim, Jung Lim, et al.
Publicado: (2019)

Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis
por: Chen, Shuzhen, et al.
Publicado: (2010)

The Combination of TRAIL Treatment and Cancer Cell Selective Expression of TRAIL-Death Receptor DR4 Induces Cell Death in TRAIL-Resistant Cancer Cells
por: Choi, Eunah, et al.
Publicado: (2006)

TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ
por: Fossati, S, et al.
Publicado: (2012)

TRAIL DR5-CTSB crosstalk participates in breast cancer autophagy initiated by SAHA
por: Han, Han, et al.
Publicado: (2017)

Potentiation of TRAIL-Induced Apoptosis in TRAIL-Resistant Cholangiocarcinoma Cells by Curcumin through the Induction of DR5 Membrane Localization and Disruption of the Anti-Apoptotic Complex DR5/DDX3/GSK3β
por: Visitnonthachai, Daranee, et al.
Publicado: (2023)

Dr. Paris, Dr. Beck, Dr. Smith, Dr. Male and Others, on Infanticide
Publicado: (1824)

Extracellular acidity enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis via DR5 in gastric cancer cells
por: Hong, Ran, et al.
Publicado: (2018)

Endocytosis and Recycling of the HIV Coreceptor Ccr5
por: Signoret, Nathalie, et al.
Publicado: (2000)

Endocytosis and Recycling of Tight Junction Proteins in Inflammation
por: Utech, Markus, et al.
Publicado: (2010)

Expression of TRAIL-R2 (DR5) on fibroblasts from synovial fluid of rheumatoid arthritis
por: Miranda, E, et al.
Publicado: (2004)

STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma
por: Simpson, Haley M., et al.
Publicado: (2018)

Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells
por: Shlyakhtina, Yelyzaveta, et al.
Publicado: (2017)

Lestaurtinib potentiates TRAIL‐induced apoptosis in glioma via CHOP‐dependent DR5 induction
por: Cao, Yingxiao, et al.
Publicado: (2020)

Non-Thermal Plasma Couples Oxidative Stress to TRAIL Sensitization through DR5 Upregulation
por: Hwang, Soon Young, et al.
Publicado: (2020)

Thymoquinone Crosstalks with DR5 to Sensitize TRAIL Resistance and Stimulate ROS-Mediated Cancer Apoptosis
por: Abd-Rabou, Ahmed A, et al.
Publicado: (2021)

TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake
por: Toffoli, Barbara, et al.
Publicado: (2021)

Macrophage-like THP-1 Cells Derived from High-Density Cell Culture Are Resistant to TRAIL-Induced Cell Death via Down-Regulation of Death-Receptors DR4 and DR5
por: Lomovskaya, Yana Vladimirovna, et al.
Publicado: (2022)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Dr. Storer on Dr. Simpson
Publicado: (1870)

Kentucky: Death of Dr. Miller, Dr. Linthicum, and Dr. Cosby
Publicado: (1867)

Necrological: Dr. Wagley, Dr. Paine, Dr. DeSteiger
Publicado: (1894)

Hepatitis C Virus Sensitizes Host Cells to TRAIL-Induced Apoptosis by Up-Regulating DR4 and DR5 via a MEK1-Dependent Pathway
por: Deng, Zhongfan, et al.
Publicado: (2012)

Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner
por: Chen, Minghui, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4od345t10bs743djh5e02cdmhi